ophthalmologytimes12h
Over 300 patients randomized in Ocular Therapeutix's SOL-1 phase 3 trial for OTX-TKI
SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug ...
ophthalmologytimes13h
EyePoint doses first patient in second global Phase 3 LUCIA clinical trial of Duravyu for the treatment of wet AMD
EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates ...
ophthalmologytimes13h
Prevent Blindness providing free educational resources on geographic atrophy
Prevent Blindness announces its fourth annual Geographic Atrophy Awareness Week, December 2 to 8, 2024. The organization ...